TORONTO, Feb. 13, 2018 (GLOBE NEWSWIRE) — Scythian Biosciences Corp. (the “Company” or “Scythian”) (TSXV:SCYB) (Frankfurt:9SB) (OTCQB:SCCYF) is pleased to announce that it has today closed its previously announced “bought deal” short form prospectus offering, including the full exercise of the over-allotment option (the “Offering”).